Soluble endoglin and other circulating antiangiogenic factors in preeclampsia
- PMID: 16957146
- DOI: 10.1056/NEJMoa055352
Soluble endoglin and other circulating antiangiogenic factors in preeclampsia
Erratum in
- N Engl J Med. 2006 Oct 26;355(17):1840
Abstract
Background: Alterations in circulating soluble fms-like tyrosine kinase 1 (sFlt1), an antiangiogenic protein, and placental growth factor (PlGF), a proangiogenic protein, appear to be involved in the pathogenesis of preeclampsia. Since soluble endoglin, another antiangiogenic protein, acts together with sFlt1 to induce a severe preeclampsia-like syndrome in pregnant rats, we examined whether it is associated with preeclampsia in women.
Methods: We performed a nested case-control study of healthy nulliparous women within the Calcium for Preeclampsia Prevention trial. The study included all 72 women who had preterm preeclampsia (<37 weeks), as well as 480 randomly selected women--120 women with preeclampsia at term (at > or =37 weeks), 120 women with gestational hypertension, 120 normotensive women who delivered infants who were small for gestational age, and 120 normotensive controls who delivered infants who were not small for gestational age.
Results: Circulating soluble endoglin levels increased markedly beginning 2 to 3 months before the onset of preeclampsia. After the onset of clinical disease, the mean serum level in women with preterm preeclampsia was 46.4 ng per milliliter, as compared with 9.8 ng per milliliter in controls (P<0.001). The mean serum level in women with preeclampsia at term was 31.0 ng per milliliter, as compared with 13.3 ng per milliliter in controls (P<0.001). Beginning at 17 weeks through 20 weeks of gestation, soluble endoglin levels were significantly higher in women in whom preterm preeclampsia later developed than in controls (10.2 ng per milliliter vs. 5.8 ng per milliliter, P<0.001), and at 25 through 28 weeks of gestation, the levels were significantly higher in women in whom term preeclampsia developed than in controls (8.5 ng per milliliter vs. 5.9 ng per milliliter, P<0.001). An increased level of soluble endoglin was usually accompanied by an increased ratio of sFlt1:PlGF. The risk of preeclampsia was greatest among women in the highest quartile of the control distributions for both biomarkers but not for either biomarker alone.
Conclusions: Rising circulating levels of soluble endoglin and ratios of sFlt1:PlGF herald the onset of preeclampsia.
Copyright 2006 Massachusetts Medical Society.
Comment in
-
Explaining and predicting preeclampsia.N Engl J Med. 2006 Sep 7;355(10):1056-8. doi: 10.1056/NEJMe068161. N Engl J Med. 2006. PMID: 16957153 No abstract available.
Similar articles
-
Prospective study of placental angiogenic factors and maternal vascular function before and after preeclampsia and gestational hypertension.Circulation. 2010 Aug 3;122(5):478-87. doi: 10.1161/CIRCULATIONAHA.109.895458. Epub 2010 Jul 19. Circulation. 2010. PMID: 20644016
-
Circulating angiogenic factors and the risk of preeclampsia.N Engl J Med. 2004 Feb 12;350(7):672-83. doi: 10.1056/NEJMoa031884. Epub 2004 Feb 5. N Engl J Med. 2004. PMID: 14764923
-
Angiogenic factor imbalance early in pregnancy predicts adverse outcomes in patients with lupus and antiphospholipid antibodies: results of the PROMISSE study.Am J Obstet Gynecol. 2016 Jan;214(1):108.e1-108.e14. doi: 10.1016/j.ajog.2015.09.066. Epub 2015 Sep 29. Am J Obstet Gynecol. 2016. PMID: 26432463 Free PMC article.
-
Accuracy of circulating placental growth factor, vascular endothelial growth factor, soluble fms-like tyrosine kinase 1 and soluble endoglin in the prediction of pre-eclampsia: a systematic review and meta-analysis.BJOG. 2012 Jun;119(7):778-87. doi: 10.1111/j.1471-0528.2012.03311.x. Epub 2012 Mar 20. BJOG. 2012. PMID: 22433027 Review.
-
Abnormal blood biomarkers in early pregnancy are associated with preeclampsia: a meta-analysis.Eur J Obstet Gynecol Reprod Biol. 2014 Nov;182:194-201. doi: 10.1016/j.ejogrb.2014.09.027. Epub 2014 Sep 22. Eur J Obstet Gynecol Reprod Biol. 2014. PMID: 25305662 Review.
Cited by
-
Relationship between proteinuria and changes in antepartum and postpartum choroidal thickness in patients with pre-eclampsia.Sci Rep. 2024 Jun 3;14(1):12672. doi: 10.1038/s41598-024-63359-3. Sci Rep. 2024. PMID: 38830948 Free PMC article.
-
Streamlined Analysis of Maternal Plasma Indicates Small Extracellular Vesicles are Significantly Elevated in Early-Onset Preeclampsia.Reprod Sci. 2024 May 22. doi: 10.1007/s43032-024-01591-y. Online ahead of print. Reprod Sci. 2024. PMID: 38777947
-
Disruption of maternal vascular remodeling by a fetal endoretrovirus-derived gene in preeclampsia.Genome Biol. 2024 May 7;25(1):117. doi: 10.1186/s13059-024-03265-z. Genome Biol. 2024. PMID: 38715110 Free PMC article.
-
Validation of a new kit for preeclampsia screening: A comprehensive analysis.Heliyon. 2024 Mar 13;10(6):e28080. doi: 10.1016/j.heliyon.2024.e28080. eCollection 2024 Mar 30. Heliyon. 2024. PMID: 38533029 Free PMC article.
-
Soyghurt Potentially Controls the Level of sFlt1 and PLGF in Preeclampsia Maternal Serum-Induced Placental Trophoblast Cell in vitro.J Exp Pharmacol. 2024 Mar 13;16:111-122. doi: 10.2147/JEP.S446961. eCollection 2024. J Exp Pharmacol. 2024. PMID: 38504909 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
- N01-HD-1-3121/HD/NICHD NIH HHS/United States
- N01-HD-3122/HD/NICHD NIH HHS/United States
- N01-HD-3123/HD/NICHD NIH HHS/United States
- N01-HD-3124/HD/NICHD NIH HHS/United States
- N01-HD-3125/HD/NICHD NIH HHS/United States
- N01-HD-3126/HD/NICHD NIH HHS/United States
- N01-HD-3154/HD/NICHD NIH HHS/United States
- N01-HD-5-3246/HD/NICHD NIH HHS/United States
- R01 DK-065997/DK/NIDDK NIH HHS/United States
- R01 DK-67397/DK/NIDDK NIH HHS/United States
- R01 HD-39223/HD/NICHD NIH HHS/United States
- R01 HL-079594/HL/NHLBI NIH HHS/United States
- Intramural NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous